EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA authorizes Mounjaro (tirzepatide) for therapeutic use in type 2 diabetes, obesity, and overweight conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight
• Type 2 Diabetes Mellitus

Drugs mentioned

• MOUNJARO (tirzepatide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Obesity;Overweight. MAH: Eli Lilly Nederland B.V.. Decision date: 25/06/2026